SurVaxM Misses Overall Phase IIb Survival Endpoint

Company MimiVax Event Type Phase 2b topline result (primary endpoint missed; subgroup signal) Modality Peptide cancer vaccine (survivin-targeted) Asset SurVaxM Target Survivin Disease Area Newly diagnosed glioblastoma Summary MimiVax reported that SurVaxM plus standard therapy did not meet the overall-survival primary endpoint in the randomized…